Santos R D, Mansur A P, Safi Júnior J, Giraldez R R, Maranhão R C, Pileggi F, Ramires J A
Instituto do Coração do Hospital das Clínicas, FMUSP.
Arq Bras Cardiol. 1995 Aug;65(2):181-3.
To evaluate the effects of gemfibrozil and pravastatin in coronary artery disease patients with HDL-cholesterol (HDL-C) < 35 mg/dl).
Twenty-nine patients (20 males, 60 +/- 9) were divided in a gemfibrozil group (G) (1200 mg/day n = 15) and a pravastatin group (P) (10 or 20 mg n = 10 and 4, respectively). The plasma lipid profile (LP) e.g. total cholesterol (TC), fractions and triglycerides (TG) was determined at 4 and 12 weeks of treatment.
HDL-C was not affected in P, TC and LDL-cholesterol (LDL-C) reductions were superior to those in G (31.3% vs 13.4% and 38.7 and 11.5%, p < 0.05 and < 0.01 respectively). In G HDL-C raised by 50% (12th week p < 0.01). Gemfibrozil reduced TG levels in 44.7% while in P it varied -32.2% (12th week p < 0.01 and < 0.05 respectively).
Gemfibrozil is more effective in reducing TG and raising HDL-C than pravastatin. On the other hand, pravastatin was more potent in reducing LDL-C levels.
评估吉非贝齐和普伐他汀对高密度脂蛋白胆固醇（HDL-C）<35mg/dl的冠心病患者的影响。
29例患者（20例男性，60±9岁）分为吉非贝齐组（G组）（1200mg/天，n = 15）和普伐他汀组（P组）（10mg或20mg，分别为n = 10和4）。在治疗4周和12周时测定血浆脂质谱（LP），例如总胆固醇（TC）、各组分和甘油三酯（TG）。
P组中HDL-C未受影响，TC和低密度脂蛋白胆固醇（LDL-C）的降低优于G组（分别为31.3%对13.4%以及38.7%对11.5%，p分别<0.05和<0.01）。在G组中，HDL-C升高了50%（第12周，p<0.01）。吉非贝齐使TG水平降低44.7%，而在P组中变化为-32.2%（第12周，p分别<0.01和<0.05）。
与普伐他汀相比，吉非贝齐在降低TG和升高HDL-C方面更有效。另一方面，普伐他汀在降低LDL-C水平方面更有效。
